• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

by Elizabeth | Jan 26, 2026 | News

Paris and Boston, January 26, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) announces today the initiation of coverage of its stock by...
Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums

by Elizabeth | Jan 21, 2026 | News

Paris and Boston, January 21, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its financial calendar for the...
Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. 

by Elizabeth | Jan 15, 2026 | News

 Q4 2025 revenue up 19% on a reported basis (+29% excluding currency effects – CER)  Sales in the United States up 65% (+82% at CER) after three consecutive quarters of acceleration (+11%, +23%, +31% at CER), driven by pancreatic cyst indication CellTolerance...
Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management 

by Elizabeth | Dec 3, 2025 | News

Integrating Cellvizio® into TaeWoong’s portfolio of therapeutic devices to create the first fully integrated “imaging-to-therapy” solution for EUS-guided pancreatic care  Los Angeles, Paris and Boston, December 3, 2025 – 6:00 p.m. CET – Mauna Kea Technologies...
Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 

Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform 

by Elizabeth | Nov 20, 2025 | News, News

NMPA approval obtained following a 3-year certification process  Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China independently of the JV with Tasly Paris and Boston, November 20, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext...
« Older Entries

Articles récents

  • Mauna Kea Technologies announces Initiation of Coverage by Allinvest Securities 
  • Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums
  • Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. 
  • Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management 
  • Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}